Eloctate
Total Payments
$680,111
Transactions
631
Doctors
91
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $20,446 | 4 | 1 |
| 2022 | $5,918 | 2 | 1 |
| 2018 | $190,603 | 148 | 21 |
| 2017 | $463,144 | 477 | 74 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $452,559 | 373 | 66.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $191,469 | 39 | 28.2% |
| Travel and Lodging | $29,686 | 56 | 4.4% |
| Food and Beverage | $5,743 | 141 | 0.8% |
| Education | $405.35 | 21 | 0.1% |
| Consulting Fee | $247.71 | 1 | 0.0% |
Payments by Type
Research
$452,559
373 transactions
General
$227,551
258 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein Known as rFVIIIFc in Untreated Males With Severe Hemophilia A | Bioverativ Therapeutics Inc. | $242,861 | 0 |
| Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L 15K Scale | Bioverativ Therapeutics Inc. | $61,227 | 0 |
| Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction ITI in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment | Bioverativ Therapeutics Inc. | $58,838 | 0 |
| Sobi.Elocta-003 | Swedish Orphan Biovitrum AB | $57,152 | 0 |
| Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A | Bioverativ Therapeutics Inc. | $22,860 | 0 |
| A Phase 12a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN BIVV001 in Previously Treated Adults With Severe Hemophilia A | Bioverativ Therapeutics Inc. | $9,622 | 0 |
Top Doctors Receiving Payments for Eloctate
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Iowa City, IA | $532,584 | 389 |
| , M.D., M.P.H | Pediatric Hematology-Oncology | Loxahatchee, FL | $28,452 | 39 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $26,411 | 17 |
| , M.D | Pediatric Hematology-Oncology | Ann Arbor, MI | $20,446 | 4 |
| , M.D | Hematology | Los Angeles, CA | $19,935 | 13 |
| , M.D | Pediatric Hematology-Oncology | Madera, CA | $13,464 | 15 |
| , MD, MPH | Pediatrics | Pittsburgh, PA | $9,851 | 11 |
| , M.D | Internal Medicine | Salt Lake City, UT | $8,374 | 10 |
| , M.D., PHD | Hematology & Oncology | Sacramento, CA | $6,562 | 4 |
| , MD | Hematology & Oncology | Milwaukee, WI | $5,918 | 2 |
| , MD | Internal Medicine | Cleveland, OH | $1,402 | 5 |
| , MD | Pediatrics | Cleveland, OH | $1,007 | 3 |
| , MD | Hematology & Oncology | Philadelphia, PA | $936.84 | 3 |
| , MO | Pediatric Hematology-Oncology | Pacheco, CA | $375.14 | 2 |
| , MD | Pediatric Hematology-Oncology | Pacheco, CA | $375.14 | 2 |
| , M.D | Hematology & Oncology | Cleveland, OH | $353.65 | 1 |
| , M.D | Psychiatry | Sarasota, FL | $306.47 | 2 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $181.22 | 1 |
| , MD | Pediatric Hematology-Oncology | Kansas City, MO | $131.65 | 1 |
| , DO | Pediatric Hematology-Oncology | Kansas City, MO | $131.65 | 1 |
| , MDCM, MPH | Pediatric Hematology-Oncology | Kansas City, MO | $131.65 | 1 |
| , M.D | Anesthesiology | Albuquerque, NM | $121.85 | 1 |
| , MD | Hematology & Oncology | Chapel Hill, NC | $110.72 | 1 |
| , MD | Hematology & Oncology | Washington, DC | $102.02 | 3 |
| , M.D | Pediatrics | Fairview, TX | $98.26 | 1 |
Ad
Manufacturing Companies
- Bioverativ Therapeutics Inc. $596,596
- Swedish Orphan Biovitrum AB $77,597
- SWEDISH ORPHAN BIOVITRUM AB $5,918
Product Information
- Type Drug
- Total Payments $680,111
- Total Doctors 91
- Transactions 631
About Eloctate
Eloctate is a drug associated with $680,111 in payments to 91 healthcare providers, recorded across 631 transactions in the CMS Open Payments database. The primary manufacturer is Bioverativ Therapeutics Inc..
Payment data is available from 2017 to 2023. In 2023, $20,446 was paid across 4 transactions to 1 doctors.
The most common payment nature for Eloctate is "Unspecified" ($452,559, 66.5% of total).
Eloctate is associated with 6 research studies, including "An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein Known as rFVIIIFc in Untreated Males With Severe Hemophilia A" ($242,861).